Interaction between the extracellular matrix and lymphatics: Consequences for lymphangiogenesis and lymphatic function

Matrix Biology

Volumn 29, Issue 8, 2010, Pages 645-656

  Wiig, Helge ^a   Keskin, Doruk ^a   Kalluri, Raghu ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Integrins; Lymphedema; Metastasis; Microenvironment; Tumor stroma

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN; EMILIN 1; FIBRONECTIN; GLYCOPROTEIN; HYALURONIC ACID; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; TENASCIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VOLOCIXIMAB;

DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHEDEMA; METASTASIS; MICROENVIRONMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; NEOPLASMS;

EID: 78649450413     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2010.08.001     Document Type: Review

References (175)

1. Achen M.G., Stacker S.A. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int. J. Cancer 2006, 119:1755-1760.
2. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 1998, 95:548-553.
3. Achen M.G., McColl B.K., Stacker S.A. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005, 7:121-127.
4. Adair T.H., Moffatt D.S., Paulsen A.W., Guyton A.C. Quantitation of changes in lymph protein concentration during lymph node transit. Am. J. Physiol. 1982, 243:H351-H359.
5. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
6. Allan A.L., George R., Vantyghem S.A., Lee M.W., Hodgson N.C., Engel C.J., Holliday R.L., Girvan D.P., Scott L.A., Postenka C.O., et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am. J. Pathol. 2006, 169:233-246.
7. Aszodi A., Legate K.R., Nakchbandi I., Fassler R. What mouse mutants teach us about extracellular matrix function. Annu. Rev. Cell Dev. Biol. 2006, 22:591-621.
8. Aukland K., Reed R.K. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 1993, 73:1-78.
9. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617.
10. Azzali G. Transendothelial transport and migration in vessels of the apparatus lymphaticus periphericus absorbens (ALPA). Int. Rev. Cytol. 2003, 230:41-87.
11. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., Vestweber D., Corada M., Molendini C., Dejana E., et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 2007, 204:2349-2362.
12. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., Jones M., Jackson D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144:789-801.
13. Banziger-Tobler N.E., Halin C., Kajiya K., Detmar M. Growth hormone promotes lymphangiogenesis. Am. J. Pathol. 2008, 173:586-597.
14. Bates D.O., Levick J.R., Mortimer P.S. Change in macromolecular composition of interstitial fluid from swollen arms after breast cancer treatment, and its implications. Clin. Sci. (Lond.) 1993, 85:737-746.
15. Bazigou E., Xie S., Chen C., Weston A., Miura N., Sorokin L., Adams R., Muro A.F., Sheppard D., Makinen T. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev. Cell 2009, 17:175-186.
16. Bjorndahl M., Cao R., Nissen L.J., Clasper S., Johnson L.A., Xue Y., Zhou Z., Jackson D., Hansen A.J., Cao Y. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15593-15598.
17. Boardman K.C., Swartz M.A. Interstitial flow as a guide for lymphangiogenesis. Circ. Res. 2003, 92:801-808.
18. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2007, 48:2545-2552.
19. Brakenhielm E., Burton J.B., Johnson M., Chavarria N., Morizono K., Chen I., Alitalo K., Wu L. Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int. J. Cancer 2007, 121:2153-2161.
20. Breiteneder-Geleff S., Soleiman A., Kowalski H., Horvat R., Amann G., Kriehuber E., Diem K., Weninger W., Tschachler E., Alitalo K., et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999, 154:385-394.
21. Bressan G.M., Daga-Gordini D., Colombatti A., Castellani I., Marigo V., Volpin D. Emilin, a component of elastic fibers preferentially located at the elastin-microfibrils interface. J. Cell Biol. 1993, 121:201-212.
22. Brideau G., Makinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., Pihlajaniemi T., Heljasvaara R. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 2007, 67:11528-11535.
23. Bruyere F., Melen-Lamalle L., Blacher S., Roland G., Thiry M., Moons L., Frankenne F., Carmeliet P., Alitalo K., Libert C., et al. Modeling lymphangiogenesis in a three-dimensional culture system. Nat. Methods 2008, 5:431-437.
24. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., Alitalo K., Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68:7828-7837.
25. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumour progression. Nat. Rev. Cancer 2009, 9:108-122.
26. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 2005, 5:735-743.
27. Cao R., Bjorndahl M.A., Religa P., Clasper S., Garvin S., Galter D., Meister B., Ikomi F., Tritsaris K., Dissing S., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004, 6:333-345.
28. Casley-Smith J.R., Gaffney R.M. Excess plasma proteins as a cause of chronic inflammation and lymphodema: quantitative electron microscopy. J. Pathol. 1981, 133:243-272.
29. Cheresh D.A., Stupack D.G. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 2008, 27:6285-6298.
30. Chiquet M., Gelman L., Lutz R., Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim. Biophys. Acta 2009, 1793:911-920.
31. Chung I.S., Son Y.I., Ko Y.J., Baek C.H., Cho J.K., Jeong H.S. Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol. 2008, 44:1118-1126.
32. Clamp A.R., Jayson G.C. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br. J. Cancer 2005, 93:967-972.
33. Clasper S., Royston D., Baban D., Cao Y., Ewers S., Butz S., Vestweber D., Jackson D.G. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 2008, 68:7293-7303.
34. Clavin N.W., Avraham T., Fernandez J., Daluvoy S.V., Soares M.A., Chaudhry A., Mehrara B.J. TGF-beta1 is a negative regulator of lymphatic regeneration during wound repair. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2113-H2127.
35. Coffelt S.B., Hughes R., Lewis C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 2009, 1796:11-18.
36. Cohen-Kaplan V., Naroditsky I., Zetser A., Ilan N., Vlodavsky I., Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 2008, 123:2566-2573.
37. Conrad C., Niess H., Huss R., Huber S., von Luettichau I., Nelson P.J., Ott H.C., Jauch K.W., Bruns C.J. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation 2009, 119:281-289.
38. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
39. Crawford Y., Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335:261-269.
40. Danussi C., Spessotto P., Petrucco A., Wassermann B., Sabatelli P., Montesi M., Doliana R., Bressan G.M., Colombatti A. Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Mol. Cell. Biol. 2008, 28:4026-4039.
41. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97:1093-1107.
42. Dietrich T., Onderka J., Bock F., Kruse F.E., Vossmeyer D., Stragies R., Zahn G., Cursiefen C. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am. J. Pathol. 2007, 171:361-372.
43. Durbeej M. Laminins. Cell Tissue Res. 2009, 339:259-268.
44. El-Chemaly S., Malide D., Zudaire E., Ikeda Y., Weinberg B.A., Pacheco-Rodriguez G., Rosas I.O., Aparicio M., Ren P., MacDonald S.D., et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3958-3963.
45. Fiorilli P., Partridge D., Staniszewska I., Wang J.Y., Grabacka M., So K., Marcinkiewicz C., Reiss K., Khalili K., Croul S.E. Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation. Lab. Invest. 2008, 88:1143-1156.
46. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
47. Fritz-Six K.L., Dunworth W.P., Li M., Caron K.M. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J. Clin. Invest. 2008, 118:40-50.
48. Fukumoto S., Morifuji M., Katakura Y., Ohishi M., Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin. Exp. Metastasis 2005, 22:31-38.
49. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
50. Gale N.W., Prevo R., Espinosa J., Ferguson D.J., Dominguez M.G., Yancopoulos G.D., Thurston G., Jackson D.G. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol. Cell. Biol. 2007, 27:595-604.
51. Garmy-Susini B., Makale M., Fuster M., Varner J.A. Methods to study lymphatic vessel integrins. Methods Enzymol. 2007, 426:415-438.
52. Garmy-Susini B., Avraamides C.J., Schmid M.C., Foubert P., Ellies L.G., Barnes L., Feral C., Papayannopoulou T., Lowy A., Blair S.L., et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010, 70:3042-3051.
53. Gelse K., Poschl E., Aigner T. Collagens-structure, function, and biosynthesis. Adv. Drug Deliv. Rev. 2003, 55:1531-1546.
54. Gerli R., Solito R., Weber E., Agliano M. Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology 2000, 33:148-157.
55. Goldman J., Conley K.A., Raehl A., Bondy D.M., Pytowski B., Swartz M.A., Rutkowski J.M., Jaroch D.B., Ongstad E.L. Regulation of lymphatic capillary regeneration by interstitial flow in skin. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2176-H2183.
56. Hahn C., Schwartz M.A. Mechanotransduction in vascular physiology and atherogenesis. Nat. Rev. Mol. Cell Biol. 2009, 10:53-62.
57. Hakkinen L., Hildebrand H.C., Berndt A., Kosmehl H., Larjava H. Immunolocalization of tenascin-C, alpha9 integrin subunit, and alphavbeta6 integrin during wound healing in human oral mucosa. J. Histochem. Cytochem. 2000, 48:985-998.
58. Harvey N.L., Srinivasan R.S., Dillard M.E., Johnson N.C., Witte M.H., Boyd K., Sleeman M.W., Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 2005, 37:1072-1081.
59. Heino J. The collagen family members as cell adhesion proteins. Bioessays 2007, 29:1001-1010.
60. Hogan B.M., Bos F.L., Bussmann J., Witte M., Chi N.C., Duckers H.J., Schulte-Merker S. Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat. Genet. 2009, 41:396-398.
61. Hong Y.K., Harvey N., Noh Y.H., Schacht V., Hirakawa S., Detmar M., Oliver G. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev. Dyn. 2002, 225:351-357.
62. Hong Y.K., Lange-Asschenfeldt B., Velasco P., Hirakawa S., Kunstfeld R., Brown L.F., Bohlen P., Senger D.R., Detmar M. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J. 2004, 18:1111-1113.
63. Hsia H.C., Schwarzbauer J.E. Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 2005, 280:26641-26644.
64. Huang X.Z., Wu J.F., Ferrando R., Lee J.H., Wang Y.L., Farese R.V., Sheppard D. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol. Cell. Biol. 2000, 20:5208-5215.
65. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
66. Hynes R.O. Cell-matrix adhesion in vascular development. J. Thromb. Haemost. 2007, 5(Suppl 1):32-40.
67. Jackson D.G. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol. Rev. 2009, 230:216-231.
68. Jeon B.H., Jang C., Han J., Kataru R.P., Piao L., Jung K., Cha H.J., Schwendener R.A., Jang K.Y., Kim K.S., et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008, 68:1100-1109.
69. Ji R.C. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat. Res. Biol. 2006, 4:83-100.
70. Ji R.C. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev. 2006, 25:677-694.
71. Jones F.S., Jones P.L. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dyn. 2000, 218:235-259.
72. Joshi P., Chung C.Y., Aukhil I., Erickson H.P. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J. Cell Sci. 1993, 106(Pt 1):389-400.
73. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:290-298.
74. Junt T., Moseman E.A., Iannacone M., Massberg S., Lang P.A., Boes M., Fink K., Henrickson S.E., Shayakhmetov D.M., Di Paolo N.C., et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007, 450:110-114.
75. Jurisic G., Detmar M. Lymphatic endothelium in health and disease. Cell Tissue Res. 2009, 335:97-108.
76. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3566-3570.
77. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005, 24:2885-2895.
78. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
79. Karkkainen M.J., Saaristo A., Jussila L., Karila K.A., Lawrence E.C., Pajusola K., Bueler H., Eichmann A., Kauppinen R., Kettunen M.I., et al. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12677-12682.
80. Karlsen T.V., Karkkainen M.J., Alitalo K., Wiig H. Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. J. Physiol. 2006, 574:583-596.
81. Karpanen T., Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol. 2008, 3:367-397.
82. Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol. Rev. 2004, 84:649-698.
83. Knight K.R., Collopy P.A., McCann J.J., Vanderkolk C.A., Coe S.A., Barton R.M., Chen H.C., O'Brien B.M. Protein metabolism and fibrosis in experimental canine obstructive lymphedema. J. Lab. Clin. Med. 1987, 110:558-566.
84. Kojima T., Azar D.T., Chang J.H. Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett. 2008, 582:2515-2520.
85. Koyama H., Kobayashi N., Harada M., Takeoka M., Kawai Y., Sano K., Fujimori M., Amano J., Ohhashi T., Kannagi R., et al. Significance of tumor-associated stroma in promotion of intratumoral lymphangiogenesis: pivotal role of a hyaluronan-rich tumor microenvironment. Am. J. Pathol. 2008, 172:179-193.
86. Leak L.V. The structure of lymphatic capillaries in lymph formation. Fed. Proc. 1976, 35:1863-1871.
87. Leak L.V., Jones M. Lymphangiogenesis in vitro: formation of lymphatic capillary-like channels from confluent monolayers of lymphatic endothelial cells. In Vitro Cell. Dev. Biol. Anim. 1994, 30A:512-518.
88. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
89. Liang P., Hong J.W., Ubukata H., Liu G., Katano M., Motohashi G., Kasuga T., Watanabe Y., Nakada I., Tabuchi T. Myofibroblasts correlate with lymphatic microvessel density and lymph node metastasis in early-stage invasive colorectal carcinoma. Anticancer Res. 2005, 25:2705-2712.
90. Liao Y.F., Gotwals P.J., Koteliansky V.E., Sheppard D., Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J. Biol. Chem. 2002, 277:14467-14474.
91. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
92. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154-165.
93. Ma G.C., Liu C.S., Chang S.P., Yeh K.T., Ke Y.Y., Chen T.H., Wang B.B., Kuo S.J., Shih J.C., Chen M. A recurrent ITGA9 missense mutation in human fetuses with severe chylothorax: possible correlation with poor response to fetal therapy. Prenat. Diagn. 2008, 28:1057-1063.
94. Mackie E.J., Tucker R.P. The tenascin-C knockout revisited. J. Cell Sci. 1999, 112(Pt 22):3847-3853.
95. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7:199-205.
96. Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D., et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001, 20:4762-4773.
97. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
98. Marcinkiewicz C., Taooka Y., Yokosaki Y., Calvete J.J., Marcinkiewicz M.M., Lobb R.R., Niewiarowski S., Sheppard D. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin. J. Biol. Chem. 2000, 275:31930-31937.
99. Matsuo M., Sakurai H., Koizumi K., Saiki I. Curcumin inhibits the formation of capillary-like tubes by rat lymphatic endothelial cells. Cancer Lett. 2007, 251:288-295.
100. McGeown J.G., McHale N.G., Thornbury K.D. The effect of electrical stimulation of the sympathetic chain on peripheral lymph flow in the anaesthetized sheep. J. Physiol. 1987, 393:123-133.
101. McHale N.G., Roddie I.C. The effect of transmural pressure on pumping activity in isolated bovine lymphatic vessels. J. Physiol. 1976, 261:255-269.
102. Miner J.H., Yurchenco P.D. Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 2004, 20:255-284.
103. Mishima K., Watabe T., Saito A., Yoshimatsu Y., Imaizumi N., Masui S., Hirashima M., Morisada T., Oike Y., Araie M., et al. Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. Mol. Biol. Cell 2007, 18:1421-1429.
104. Morisada T., Oike Y., Yamada Y., Urano T., Akao M., Kubota Y., Maekawa H., Kimura Y., Ohmura M., Miyamoto T., et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005, 105:4649-4656.
105. Mumprecht V., Detmar M. Lymphangiogenesis and cancer metastasis. J. Cell. Mol. Med. 2009, 13:1405-1416.
106. Muthuchamy M., Zawieja D. Molecular regulation of lymphatic contractility. Ann. N.Y. Acad. Sci. 2008, 1131:89-99.
107. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
108. Nakamura E.S., Koizumi K., Kobayashi M., Saiki I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci. 2004, 95:25-31.
109. Nathan S.S., Huvos A.G., Casas-Ganem J.E., Yang R., Linkov I., Sowers R., DiResta G.R., Gorlick R., Healey J.H. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J. Orthop. Res. 2008, 26:1520-1525.
110. Ng C.P., Helm C.L., Swartz M.A. Interstitial flow differentially stimulates blood and lymphatic endothelial cell morphogenesis in vitro. Microvasc. Res. 2004, 68:258-264.
111. Nyberg P., Salo T., Kalluri R. Tumor microenvironment and angiogenesis. Front. Biosci. 2008, 13:6537-6553.
112. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E., Weich H.A., Christ B., Alitalo K., Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 1997, 188:96-109.
113. Oka M., Iwata C., Suzuki H.I., Kiyono K., Morishita Y., Watabe T., Komuro A., Kano M.R., Miyazono K. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 2008, 111:4571-4579.
114. Okazaki T., Ni A., Ayeni O.A., Baluk P., Yao L.C., Vossmeyer D., Zischinsky G., Zahn G., Knolle J., Christner C., et al. alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation. Am. J. Pathol. 2009, 174:2378-2387.
115. Olszewski W.L. Pathophysiological aspects of lymphedema of human limbs: I. Lymph protein composition. Lymphat. Res. Biol. 2003, 1:235-243.
116. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244:143-163.
117. Ou J.J., Wu F., Liang H.J. Colorectal tumor derived fibronectin alternatively spliced EDA domain exerts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol. Ther. 2010, 9:186-191.
118. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
119. Petrova T.V., Makinen T., Makela T.P., Saarela J., Virtanen I., Ferrell R.E., Finegold D.N., Kerjaschki D., Yla-Herttuala S., Alitalo K. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 2002, 21:4593-4599.
120. Podgrabinska S., Braun P., Velasco P., Kloos B., Pepper M.S., Skobe M. Molecular characterization of lymphatic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16069-16074.
121. Raman R., Sasisekharan V., Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem. Biol. 2005, 12:267-277.
122. Randolph G.J. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin. Immunol. 2001, 13:267-274.
123. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 2005, 5:617-628.
124. Randolph G.J., Ochando J., Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 2008, 26:293-316.
125. Rockson S.G. Lymphedema. Am. J. Med. 2001, 110:288-295.
126. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
127. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005, 9:267-285.
128. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 1999, 76:1-20.
129. Rutkowski J.M., Swartz M.A. A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol. 2007, 17:44-50.
130. Rutkowski J.M., Boardman K.C., Swartz M.A. Characterization of lymphangiogenesis in a model of adult skin regeneration. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1402-H1410.
131. Rutkowski J.M., Markhus C.E., Gyenge C.C., Alitalo K., Wiig H., Swartz M.A. Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. Am. J. Pathol. 2010, 176:1122-1129.
132. Saharinen P., Tammela T., Karkkainen M.J., Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004, 25:387-395.
133. Saito N., Hamada J., Furukawa H., Tsutsumida A., Oyama A., Funayama E., Saito A., Tsuji T., Tada M., Moriuchi T., et al. Laminin-421 produced by lymphatic endothelial cells induces chemotaxis for human melanoma cells. Pigment Cell Melanoma Res. 2009, 22:601-610.
134. Sasisekharan R., Raman R., Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu. Rev. Biomed. Eng. 2006, 8:181-231.
135. Schmid-Schonbein G.W. Microlymphatics and lymph flow. Physiol. Rev. 1990, 70:987-1028.
136. Schneider H., Harbottle R.P., Yokosaki Y., Kunde J., Sheppard D., Coutelle C. A novel peptide, PLAEIDGIELTY, for the targeting of alpha9beta1-integrins. FEBS Lett. 1998, 429:269-273.
137. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 2002, 161:947-956.
138. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
139. Shin J.W., Min M., Larrieu-Lahargue F., Canron X., Kunstfeld R., Nguyen L., Henderson J.E., Bikfalvi A., Detmar M., Hong Y.K. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol. Biol. Cell 2006, 17:576-584.
140. Shinde A.V., Bystroff C., Wang C., Vogelezang M.G., Vincent P.A., Hynes R.O., Van De Water L. Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J. Biol. Chem. 2008, 283:2858-2870.
141. Shyy J.Y., Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ. Res. 2002, 91:769-775.
142. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
143. Sleeman J.P., Thiele W. Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 2009, 125:2747-2756.
144. Spinella F., Garrafa E., Di Castro V., Rosano L., Nicotra M.R., Caruso A., Natali P.G., Bagnato A. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009, 69:2669-2676.
145. Sriramarao P., Mendler M., Bourdon M.A. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J. Cell Sci. 1993, 105(Pt 4):1001-1012.
146. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7:186-191.
147. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
148. Sundar S.S., Ganesan T.S. Role of lymphangiogenesis in cancer. J. Clin. Oncol. 2007, 25:4298-4307.
149. Svendsen O.S., Barczyk M.M., Popova S.N., Liden A., Gullberg D., Wiig H. The alpha11beta1 integrin has a mechanistic role in control of interstitial fluid pressure and edema formation in inflammation. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1864-1870.
150. Swartz M.A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 2001, 50:3-20.
151. Swartz M.A., Fleury M.E. Interstitial flow and its effects in soft tissues. Annu. Rev. Biomed. Eng. 2007, 9:229-256.
152. Swartz M.A., Hubbell J.A., Reddy S.T. Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin. Immunol. 2008, 20:147-156.
153. Tabibiazar R., Cheung L., Han J., Swanson J., Beilhack A., An A., Dadras S.S., Rockson N., Joshi S., Wagner R., et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006, 3:e254.
154. Takada Y., Ye X., Simon S. The integrins. Genome Biol. 2007, 8:215.
155. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
156. Tammela T., Saaristo A., Lohela M., Morisada T., Tornberg J., Norrmen C., Oike Y., Pajusola K., Thurston G., Suda T., et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005, 105:4642-4648.
157. Taylor G.W., Kinmonth J.B., Dangerfield W.G. Protein content of oedema fluid in lymphoedema. Br. Med. J. 1958, 1:1159-1160.
158. Vainionpaa N., Butzow R., Hukkanen M., Jackson D.G., Pihlajaniemi T., Sakai L.Y., Virtanen I. Basement membrane protein distribution in LYVE-1-immunoreactive lymphatic vessels of normal tissues and ovarian carcinomas. Cell Tissue Res. 2007, 328:317-328.
159. Vlahakis N.E., Young B.A., Atakilit A., Sheppard D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J. Biol. Chem. 2005, 280:4544-4552.
160. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3:867-878.
161. von der Weid P.Y., Crowe M.J., Van Helden D.F. Endothelium-dependent modulation of pacemaking in lymphatic vessels of the guinea-pig mesentery. J. Physiol. 1996, 493(Pt 2):563-575.
162. Wang N., Tytell J.D., Ingber D.E. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat. Rev. Mol. Cell Biol. 2009, 10:75-82.
163. Wernert N., Okuducu A.F., Pepper M.S. Ets 1 is expressed in capillary blood vessels but not in lymphatics. J. Pathol. 2003, 200:561-567.
164. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98:769-778.
165. Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn M.D., Jackson D.G., Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002, 21:1505-1513.
166. Wiig H., Rubin K., Reed R.K. New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences. Acta Anaesthesiol. Scand. 2003, 47:111-121.
167. Wiig H., Gyenge C., Iversen P.O., Gullberg D., Tenstad O. The role of the extracellular matrix in tissue distribution of macromolecules in normal and pathological tissues: potential therapeutic consequences. Microcirculation 2008, 15:283-296.
168. Wong S.Y., Hynes R.O. Tumor-lymphatic interactions in an activated stromal microenvironment. J. Cell. Biochem. 2007, 101:840-850.
169. Wong S.Y., Haack H., Crowley D., Barry M., Bronson R.T., Hynes R.O. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005, 65:9789-9798.
170. Yokosaki Y., Monis H., Chen J., Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J. Biol. Chem. 1996, 271:24144-24150.
171. Yokosaki Y., Matsuura N., Higashiyama S., Murakami I., Obara M., Yamakido M., Shigeto N., Chen J., Sheppard D. Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J. Biol. Chem. 1998, 273:11423-11428.
172. Zanetti M., Braghetta P., Sabatelli P., Mura I., Doliana R., Colombatti A., Volpin D., Bonaldo P., Bressan G.M. EMILIN-1 deficiency induces elastogenesis and vascular cell defects. Mol. Cell. Biol. 2004, 24:638-650.
173. Zhang X., Groopman J.E., Wang J.F. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J. Cell. Physiol. 2005, 202:205-214.
174. Zhu C.Q., Popova S.N., Brown E.R., Barsyte-Lovejoy D., Navab R., Shih W., Li M., Lu M., Jurisica I., Penn L.Z., et al. Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11754-11759.
175. Zwaans B.M., Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc. Res. 2007, 74:145-158.